NervGen Pharma (NASDAQ:NGEN) Cut to “Strong Sell” at Wall Street Zen

Posted by Stanley Muller on Aug 18th, 2026

Wall Street Zen cut shares of NervGen Pharma (NASDAQ:NGEN – Free Report) from a hold rating to a strong sell rating in a research note issued to investors on Saturday.

Several other research firms also recently weighed in on NGEN. Leerink Partners initiated coverage on shares of NervGen Pharma in a research report on Monday, July 13th. They issued an “outperform” rating and a $10.00 target price for the company. TD Cowen started coverage on shares of NervGen Pharma in a research report on Thursday, June 11th. They set a “buy” rating on the stock. HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a research note on Tuesday, April 28th. Weiss Ratings lowered NervGen Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 4th. Finally, Zacks Research upgraded NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

View Our Latest Stock Report on NGEN

NervGen Pharma Price Performance

NGEN stock opened at $1.68 on Friday. The stock’s 50 day moving average is $1.84. The firm has a market capitalization of $135.46 million and a P/E ratio of -18.67. NervGen Pharma has a twelve month low of $1.58 and a twelve month high of $6.30.

NervGen Pharma (NASDAQ:NGEN – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.28). On average, research analysts forecast that NervGen Pharma will post -0.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in NervGen Pharma stock. Stonepine Capital Management LLC bought a new position in shares of NervGen Pharma (NASDAQ:NGEN – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 271,678 shares of the company’s stock, valued at approximately $559,657,000. Stonepine Capital Management LLC owned about 0.34% of NervGen Pharma at the end of the most recent reporting period.

NervGen Pharma Company Profile

(Get Free Report)

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.